Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Shivshankari Rajkumar
Observed name:
Rajkumar, Shivshankari
Institution:
Research Institute of the McGill University Health Centre
Observed institutions:
Institut du cancer Rosalind & Morris Goodman,
Research Institute of the McGill University Health Centre,
McGill University
ORCID:
0000-0002-7620-2464
Observed ORCID:
0000-0002-7620-2464
OpenAlex ID:
A5041589413
Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations
2018
·
Matthew Dankner
, April A. N. Rose
, et al.
·
Oncogene
·
574
Spatially mapping the immune landscape of melanoma using imaging mass cytometry
2022
·
Dan Moldoveanu
, LeeAnn Ramsay
, et al.
·
Science Immunology
·
132
Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas
2018
·
Matthew Dankner
, Mathieu Lajoie
, et al.
·
Clinical Cancer Research
·
78
Molecular characterisation of cutaneous melanoma: creating a framework for targeted and immune therapies
2016
·
Shivshankari Rajkumar
, Ian R Watson
·
British Journal of Cancer
·
61
PDF
Melanomas with concurrent BRAF non-p.V600 and NF1 loss-of-function mutations are targetable by BRAF/MEK inhibitor combination therapy
2022
·
Shivshankari Rajkumar
, Diana Berry
, et al.
·
Cell Reports
·
27
PDF
Reprogramming of Nucleotide Metabolism Mediates Synergy between Epigenetic Therapy and MAP Kinase Inhibition
2020
·
Tatiana Shorstova
, Jie Su
, et al.
·
Molecular Cancer Therapeutics
·
15
The NF1 tumor suppressor regulates PD-L1 and immune evasion in melanoma
2025
·
Diana Berry
, Dan Moldoveanu
, et al.
·
Cell Reports
·
14
Figure S1 from Reprogramming of Nucleotide Metabolism Mediates Synergy between Epigenetic Therapy and MAP Kinase Inhibition
2023
·
Tatiana Shorstova
, Jie Su
, et al.
·
1
PDF
Raw CyTOF images associated with Moldoveanu et al. 2022, Science Immunology
2022
·
Moldoveanu, Dan
, Ramsay, LeeAnn
, et al.
·
Zenodo (CERN European Organization for Nuclear Research)
·
1
Abstract B056: Non-V600 BRAF mutations in melanoma: actionable targets for rational drug combinations
2018
·
April A.N. Rose
, Matthew Dankner
, et al.
·
Molecular Cancer Therapeutics
·
1
Evaluating Liquid Biopsy for Circulating Tumor DNA Detection as a Complementary Diagnostic Tool in Thyroid Nodules
2026
·
Negar Jahani
, Shivshankari Rajkumar
, et al.
·
The Journal of Liquid Biopsy
PDF
Data from Reprogramming of Nucleotide Metabolism Mediates Synergy between Epigenetic Therapy and MAP Kinase Inhibition
2023
·
Tatiana Shorstova
, Jie Su
, et al.
Tables S1, S2, S3 from Reprogramming of Nucleotide Metabolism Mediates Synergy between Epigenetic Therapy and MAP Kinase Inhibition
2023
·
Tatiana Shorstova
, Jie Su
, et al.
Figure S3 from Reprogramming of Nucleotide Metabolism Mediates Synergy between Epigenetic Therapy and MAP Kinase Inhibition
2023
·
Tatiana Shorstova
, Jie Su
, et al.
Figure S4 from Reprogramming of Nucleotide Metabolism Mediates Synergy between Epigenetic Therapy and MAP Kinase Inhibition
2023
·
Tatiana Shorstova
, Jie Su
, et al.
Supplementary Figure Legends and Materials and Methods from Reprogramming of Nucleotide Metabolism Mediates Synergy between Epigenetic Therapy and MAP Kinase Inhibition
2023
·
Tatiana Shorstova
, Jie Su
, et al.
Data from Reprogramming of Nucleotide Metabolism Mediates Synergy between Epigenetic Therapy and MAP Kinase Inhibition
2023
·
Tatiana Shorstova
, Jie Su
, et al.
Figure S2 from Reprogramming of Nucleotide Metabolism Mediates Synergy between Epigenetic Therapy and MAP Kinase Inhibition
2023
·
Tatiana Shorstova
, Jie Su
, et al.
PDF
Figure S2 from Reprogramming of Nucleotide Metabolism Mediates Synergy between Epigenetic Therapy and MAP Kinase Inhibition
2023
·
Tatiana Shorstova
, Jie Su
, et al.
Tables S1, S2, S3 from Reprogramming of Nucleotide Metabolism Mediates Synergy between Epigenetic Therapy and MAP Kinase Inhibition
2023
·
Tatiana Shorstova
, Jie Su
, et al.
Figure S4 from Reprogramming of Nucleotide Metabolism Mediates Synergy between Epigenetic Therapy and MAP Kinase Inhibition
2023
·
Tatiana Shorstova
, Jie Su
, et al.
PDF
Figure S1 from Reprogramming of Nucleotide Metabolism Mediates Synergy between Epigenetic Therapy and MAP Kinase Inhibition
2023
·
Tatiana Shorstova
, Jie Su
, et al.
Figure S3 from Reprogramming of Nucleotide Metabolism Mediates Synergy between Epigenetic Therapy and MAP Kinase Inhibition
2023
·
Tatiana Shorstova
, Jie Su
, et al.
PDF
Figures S1-S6, Table S1-S2 from Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas
2023
·
Matthew Dankner
, Mathieu Lajoie
, et al.
Supplementary legends and methods from Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas
2023
·
Matthew Dankner
, Mathieu Lajoie
, et al.
Show more works
View as search
Works count:
32
Citation count:
952
H-index:
7
I10-index:
7
Year
Topic
Type